Answers are grounded in this paper and cite their sources.
The O-glycosides 1 of the seco-CI derivative 2, which is the seco form of the simplified pharmacophoric group of the potent cytotoxic antibiotic CC-1065, show only very low toxicity. In tumor-selective cancer therapy they can be used in conjunction with conjugates of glycohydrolases and monoclonal antibodies that bind at tumor-associated antigens. The glycohydrolases cleave the prodrugs 1 and release the cytotoxic components 2.
No takes yet. Share an insight, caveat, or question.
Tietze et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: